Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Comment by Ingiboyon Sep 05, 2022 2:13pm
98 Views
Post# 34942389

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:26.08 Shiseido arbitration

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:26.08 Shiseido arbitrationMetzger you are making a big assumption here to support your argument but I don't disagree.  I also believe that the  Phase 2 Trial results are good enough for Shiseido to pursue developing the process for  commercialization.  We forget that if this process actually works the commercial value is huge. You make a good point that if Shiseido is allowed to market the process in Asia and indeed does, the value of the market for the rest of the world is massive.  That is when we will see large pharma come out of the woodwork and try to buy Replicel.

There are a lot of "ifs" here but  it boils down to RCH-01 being a viable process for hair restoration.  We will soon find out.
<< Previous
Bullboard Posts
Next >>